Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're reaching!
Go look at the analytical data man! Stop wasting your time, go spend it somewhere else.
People here are smart enough not to buy what you're selling.
LOL...Hawke is not Hawkins, you halftard
Uhh...wrong.
The entire project is based off of a Geologists work that was done in the 1950's for Gulf. Estimates were made based upon core sample analytical, factual, data.
Excitement builds due to recent confirmatory analysis completed through down hold core logs in the same zone as the initial tests done in the 1950's, along with an independent site study and report completed by Hawke.
LOL
Dog, a bit of advice. You'd better make sure you're presenting the stone hard facts, or your ass might just get popped with a slander charge.
I'm looking forward to the video.
It's strange...
...I can see L2 for some stocks, but not others.
Open.
My desk says SRSR has an ineligible level 2 symbol.
Why can't...
...I see L2 on my trading desk for SRSR?
Keep running baby!
Kim said...
...that they were trying to get on Good Morning America or the Today Show.
Hugh Damn Right
I feel a strong rebound coming on for ASFX.
We're going to run today.
We are going to rock today, boys.
Dig it, then check the other side of the lake.
the cork...
When submitting different samples for analysis, the submitter can request different ASTM standards, depending upon what they are looking for and how much they want to spend. The metal tests that I've requested in the past have been for soil, rock, and water.
We typically requested analytical results for a range of metals, not metal specific requests, because my line of business was environmental consulting (we wanted to know how much of ANY metal was in a given sample...there are standards about how much of any given metal can be in ground water, for example). Results would typically be in parts per million if in soil...if in water, then parts per billion.
However.
I worked on an elemental mercury impacted property about 3 years ago and we ordered mercury specific tests, as these were cheaper than the full gamut of metal analysis.
I guess my answer is, it depends on what you want.
I was freaking out until I saw the volume
Ah, it doesn't work with FireFox...
Works fine with IE.
Interesting, but none of the links go anywhere.
Sure does! Picking up some steam!
Money is money....
Whether it's 4th grade money or Doctoral level money...it's all the same and it's the great equalizer.
PR's need to speak to both groups.
There's a simple solution.
There needs to be an easy to understand PR put out by Keevel. Real simple. It needs to
1) Explain how Niobium is used today
2) What levels of Niobium qualify as "economical"
3) The price of Niobium
4) How much Niobium is estimated to be in the ground, along with the confirmation of presence with the first assay results
5) A projection on "if the trend continues" with respect to the core logs and the money to be made.
It needs to be explained so that a 4th grader can understand it, because these traders on the floor in wall street don't have any clue what 0.53% Nb2O5 means.
BINGO
It's the drug I'm interested in, not the share structure at this point (good or bad). If the drug does what it says it does, one of the big boys is going to scoop up GNTA in a heartbeat.
No one wants to miss out on that happening. Not even you, griff.
You said you were leaving. Your credibility is in question.
Thanks, does that mean you're leaving now?
The drug speaks for itself, griff.
You wouldn't have been allergic...
...a few days ago when this thing took a rocket ride to .009, nearly breaking into pennyland. Granted, it came back down. But the stock is extremely undervalued at this range and remains a fantastic buy.
Take a look at the last 4 PR's.
I hesitate to respond to you, because that takes the attention off of such great PR out of GNTA this morning.
But I must say, you are very predictable. Great news comes out, you show up to bash.
This is flat out fantastic news and there's no way to spin that. You can't spin it. The news speaks for itself.
Amazing news...
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes that are currently in clinical development, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.
Fantastic Tesetaxel News This Morning
Genta Initiates New Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development 01/14 08:05 AM
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)-- Genta Incorporated (GNTA:$0.0054,$-0.0007,-11.48%) announced it has initiated a new clinical trial with tesetaxel, the latest addition to Genta’s oncology product portfolio. Unlike standard taxanes such as paclitaxel (Taxol®), which must be infused intravenously, tesetaxel is administered by mouth as a capsule. The new study will examine the clinical pharmacology of the drug over a narrow dosing range around the established Phase 2 dose. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.
“Taxanes are the most widely used class of anticancer compounds,†commented Dr. Loretta M. Itri, Genta’s President, Pharmaceutical Development, and Chief Medical Officer. “Successful development of an oral taxane has been a research goal that has eluded many pharmaceutical companies. Tesetaxel has already been tested in more than 250 patients with various types of cancer in the U.S., Europe, and Japan. By eliminating serious hypersensitivity infusion reactions, as well as potentially reducing nerve damage and overcoming resistance to standard taxanes, tesetaxel may offer important new treatment options for patients with advanced cancer.â€
“Having been associated with this drug since its original Phase 1 trial, I am delighted to lead this key study that will enable the pivotal trials to proceed,†said Dr. Anthony Tolcher, Director of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX. “Completed Phase 2 studies of tesetaxel in advanced breast, colon and stomach cancer have shown promising activity. We believe the innovative development strategy created for tesetaxel may enable this drug to become the first oral taxane to achieve regulatory approval.â€
About Tesetaxel
Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, both of these agents suffer from serious safety issues, particularly hypersensitivity reactions related to intravenous infusions that are occasionally fatal and that require careful premedication and observation. Other prominent side-effects of this drug class include myelosuppression (low blood counts) and peripheral neuropathy (disabling nerve damage).
With administration as an oral capsule, tesetaxel was developed with a goal of maintaining the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and increasing patient convenience. The oral route also enables the development of novel schedules that may expand dosing options when tesetaxel is used alone or in combination with other anticancer drugs, including “all oral†chemotherapy programs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.
As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes that are currently in clinical development, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity. More than 250 patients worldwide have been treated with oral tesetaxel in Phase 1 and Phase 2 clinical trials.
Yeah, I know it's old news pal...
What I was trying to do was to draw a correlation between Genta and Phizers new outlook.
They just presented there like 2 days ago...
...it's not beyond the realm of reality to believe that they had discussions. Afterall, speakers don't show up the day of a presentation from the East Coast. They fly in for the week, hang out, have some drinks, whatever.
Genta Incorporated (GNTA:$0.0056,$-0.0005,-8.20%) announced the presentation of a progress update on the company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's (GNTA:$0.0056,$-0.0005,-8.20%) lead oncology product, in patients with advanced melanoma. The data were presented in conjunction with the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA. AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's (GNTA:$0.0056,$-0.0005,-8.20%) prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy and who are identified by a biomarker (low-normal levels of lactate dehydrogenase [LDH]). The co-primary endpoints of AGENDA are progression-free survival (PFS) and overall survival. To date, more than three-quarters of the expected total number of 300 patients have been randomized into AGENDA. A total of 77 sites in 12 countries are open in Europe, the U.S., Canada, and Australia.
WOW, Genta just presented it's cancer treatment drug at the JPMorgan Healthcare Conference in San Francisco. Genasense has also been tested on humans...
VERY INTERESTING, WOW!
I think you can cut that in half...maybe take a 3rd, for a conservative estimate...
...as there will very likely be some areas where no niobium (or very little, not worth the dig) will be found.
That calculation assumes a uniform depth and width of the contact zone over distance.
Of course, the flip side of that is that there could also be intervals of greater Niobium concentration at even greater depths and widths.
Good to be conservative, either way you slice it...awesome analytical results from the first hole.
Here is the vertical depth of the contact zone mineralization:
0.53% Nb2O5, from 23 meters to 168.5 meters. That = 142.5 meters of economical niobium.
Can someone remind me how far that contact zone stretches horizontally? Something like a mile and a half? I think it's about 1,000 feet wide.
Who's good at math? :)
Oops, go GNTA! LOL
Here we go boys, hold on tight!!
She's coming back with a vengeance.
I'd say about 5 more hole results like that one will put this stock out of reach for many people.
This really is outstanding news. Wow.
It would be expensive to mine what's under the lake, though probably feasible. Maybe this is an area they would look to after making considerable profit on the East side product.
I also noticed that the Phase I recommendation in the Hawk report is extraordinarily high. 300k for a Phase I assessment is over the top. Hopefully the Phase I will tell them more than what they already know. You could almost use the Hawk report as the Phase I for the property.